Clinical Trial Update: Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Brentuximab Vedotin in combination with Bendamustine for Hodgkin lymphoma and anaplastic large cell lymphoma. The study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Columbia University | Conditions: Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED